H19 and cancer: Indeed, a number of studies have shown a predominant activation of IGF2 fetal promoters (p2–p4) in a variety of cancers displaying IGF2 increased expression levels, with variable uncoupling of DMR0–2 methylation, along with monoallelic IGF2 and/or H19 expression [47,48,49,50,51,52,53,54,55,56].